Tag: NCT03142334

Home / NCT03142334

Categories

Pembrolizumab is approved for adjuvant treatment of renal cell carcinoma

Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or ...
nct03142334

Scan the code